We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CALL
Exelixis
EXEL
$14.1B
| $310K | 0.27% |
190,700
+1,000
| +0.5% | +$5.76K |
|
77
CALL
Verizon
VZ
$182B
| $285K | 0.24% |
50,000
-7,500
| -13% | -$389K |
|
78
PUT
Synaptics
SYNA
$4.46B
| $276K | 0.24% |
+11,600
| New | +$797K |
|
79
Infosys
INFY
$46.5B
| $274K | 0.24% |
+30,714
| New | +$287K |
|
80
CALL
Colgate-Palmolive
CL
$74.4B
| $271K | 0.23% |
304,000
+177,200
| +140% | +$12.6M |
|
81
Western Digital
WDC
$164B
| $265K | 0.23% |
7,409
+4,829
| +187% | +$159K |
|
|
SAGE
82
DELISTED
Sage Therapeutics
SAGE
| $264K | 0.23% |
+8,773
| New | +$293K |
|
|
NBIS
83
Nebius Group N.V.
NBIS
$45.1B
| $264K | 0.23% |
+12,100
| New | +$235K |
|
|
TSRO
84
PUT
DELISTED
TESARO, Inc.
TSRO
| $262K | 0.23% |
+161,400
| New | +$7.2M |
|
|
PNK
85
DELISTED
Pinnacle Entertainment Inc.
PNK
| $260K | 0.22% |
+23,500
| New | +$454K |
|
86
PUT
Alibaba
BABA
$276B
| $256K | 0.22% |
11,100
| – | – |
|
|
ISEE
87
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $250K | 0.21% |
+12,000
| New | +$596K |
|
|
LUMO
88
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $247K | 0.21% |
2,434
+100
| +4% | +$12.4K |
|
89
Charter Communications
CHTR
$16.2B
| $246K | 0.21% |
+1,075
| New | +$231K |
|
90
Kohl's
KSS
$1.96B
| $246K | 0.21% |
+6,500
| New | +$258K |
|
91
PUT
Accenture
ACN
$87.9B
| $236K | 0.2% |
39,900
+13,200
| +49% | +$1.53M |
|
92
CALL
Southern Company
SO
$107B
| $231K | 0.2% |
+214,000
| New | +$10.8M |
|
93
lululemon athletica
LULU
$13.2B
| $229K | 0.2% |
+3,100
| New | +$206K |
|
|
94
CALL
Apple
AAPL
$4.9T
| $225K | 0.19% |
169,200
+57,600
| +52% | +$1.43M |
|
95
CALL
Alkermes
ALKS
$8.79B
| $225K | 0.19% |
35,500
-14,700
| -29% | -$606K |
|
96
The Mosaic Company
MOS
$7.03B
| $225K | 0.19% |
8,600
| – | – |
|
97
CALL
Johnson & Johnson
JNJ
$609B
| $224K | 0.19% |
+35,000
| New | +$3.98M |
|
98
CALL
Monster Beverage
MNST
$95.4B
| $221K | 0.19% |
151,200
+71,400
| +89% | +$1.72M |
|
99
CALL
ProShares Short VIX Short-Term Futures ETF
SVXY
$219M
| $218K | 0.19% |
+77,500
| New | +$4.19M |
|
|
ISEE
100
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $218K | 0.19% |
+4,270
| New | +$212K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.